Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598759 | 0.89 | ALDH1A1 (0.41) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL27612160 | 0.86 | ALDH1A1 (0.44) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL17277085 | 0.86 | ALDH1A1 (0.44) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| Gabapentin Enacarbil SCHEMBL977603 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| Gabapentin Enacarbil SCHEMBL25455 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL875228 | 0.81 | SLC18A2 (0.36) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL1746363 | 0.81 | ALDH1A1 (0.45) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL24785 | 0.81 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL828104 | 0.81 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA | |
| SCHEMBL828002 | 0.81 | ALDH1A1 (0.40) | ALDH1A1CYP1A2TSHRUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677767-A4 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | XENOPORT INC (US) | 2008-03-05 | — | — | EP | claimed |
| EP-1677767-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005089872-A2 | TREATMENT OF LOCAL PAIN | XENOPORT, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005037784-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20140302140-A1 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2014-10-09 | — | — | US | disclosed |
| EP-2618820-A2 | CONTROLLED RELEASE FORMULATIONS OF OPIOIDS | Qrxpharma Limited (AU) | 2013-07-31 | — | — | EP | disclosed |
| US-8299291-B2 | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs | XENOPORT, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2012040651-A2 | CONTROLLED RELEASE FORMULATIONS OF OPIOIDS | QRxPharma Ltd. (AU) | 2012-03-29 | — | — | WO | disclosed |
| EP-2403481-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG | XenoPort, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010102252-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG | XENOPORT, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1677767-A4 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | XENOPORT INC (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060257484-A1 | Combination of tramadol and substances that comprise gabapentin | JANSSEN PHARMACEUTICA N.V. | 2006-11-16 | — | — | US | disclosed |
| EP-1677767-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | Xenoport, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005089872-A2 | TREATMENT OF LOCAL PAIN | XENOPORT, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005037784-A2 | CRYSTALLINE FORM OF GAMMA-AMINOBUTYRIC ACID ANALOG | XENOPORT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | ALDH1A1 772/4885CYP1A2 251/4885TSHR 2124/4885 |
| US-20140302140-A1 | GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS | GABRB1, GABRB2, GABRA1 | ALDH1A1 144/4885CYP1A2 486/4885TSHR 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.